View which stocks have been most impacted by Coronavirus. Cellectis will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Their forecasts range from $11.00 to $73.00. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. Some companies that are related to Cellectis include Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. Export data to Excel for your own analysis. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. Interested parties can register for or listen to the call using Cellectis SA (NASDAQ:CLLS) released its earnings results on Wednesday, May, 6th.
Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. Please log in to your account or sign up in order to add this asset to your watchlist. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The biotechnology company had revenue of $51.91 million for the quarter, compared to analysts' expectations of $21.07 million. News articles about CLLS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. See Cellectis S.A. (CLLS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Want to see which stocks are moving? This suggests a possible upside of 81.2% from the stock's current price. Most stock quote data provided by BATS. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc.2019. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. It operates through two segments, Therapeutics and Plants. The company had revenue of $51.91 million for the quarter, compared to analysts' expectations of $21.07 million.
Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. CLLS stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Envestnet Asset Management Inc.. Shares of CLLS can be purchased through any online brokerage account. Cellectis saw a drop in short interest in June. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat. The company issued 3,500,000 shares at $36.83 per share. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.73%), Vident Investment Advisory LLC (0.20%), Vident Investment Advisory LLC (0.20%), Envestnet Asset Management Inc. (0.16%), Exchange Traded Concepts LLC (0.05%) and UBS Group AG (0.05%). Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO).
Cellectis trades on the NASDAQ under the ticker symbol "CLLS. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. All rights reserved. Currently, 0.6% of the company's stock are sold short. All times are ET. Disclaimer. Cellectis earned a news impact score of 1.6 on InfoTrie's scale.